Taken together, alisertib increased the expression of PD-L1 on both tumor cells and myeloid cells, and this increase strongly correlated with the impaired response to alisertib, as the loss of PD-L1 on tumor cells or systemically was associated with enhanced activity of Aurora A kinase inhibition. Here, CD274 is linked to neoplasm.